Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment
Advanced Materials · 2024-11 · 36 (44)
DOI: 10.1002/adma.202410340 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 10.09.2024. Verfasst von Sangjun Moon und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea. Hauptthemen laut MEDLINE: Tumor Microenvironment, Nanoparticles, T-Lymphocytes, Macrophages. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
T cells and macrophages have the potential to collaborate to eliminate tumor cells efficiently. Macrophages can eliminate tumor cells through phagocytosis and subsequently activate T cells by presenting tumor antigens. The activated T cells, in turn, can kill tumor cells and redirect tumor‐associated macrophages toward an antitumoral M1 phenotype. However, checkpoint molecules expressed on tumor cells impede the collaborative action of these immune cells. Meanwhile, monotherapy with a single immune checkpoint inhibitor (ICI) for either macrophages or T cells yields suboptimal efficacy in cancer patients. To address this challenge, here a nanoparticle capable of efficiently delivering dual ICIs to tumors for both macrophages and T cells is developed. These programmed cell death protein 1 (PD‐1)‐transfected macrophage membrane‐derived nanoparticles (PMMNPs) can target tumors and provide signal‐regulatory protein alpha and PD‐1 to block CD47 and programmed cell death‐ligand 1 (PD‐L1), respectively, on tumor cells. PMMNPs enhance macrophage‐mediated cancer cell phagocytosis and antigen presentation, promote T cell activation, and induce the reprogramming of macrophages toward an antitumoral phenotype. In syngeneic tumor‐bearing mice, PMMNPs demonstrate superior therapeutic efficacy compared to nanoparticles delivering single ICIs and non‐targeted delivery of anti‐CD47 and anti‐PD‐L1 antibodies. PMMNPs capable of augmenting the antitumoral interplay between macrophages and T cells may offer a promising avenue for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea.
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea.
- School of Health and Environmental Science, Korea University, Seoul, 02841, Republic of Korea.
- Institute of Engineering Research, Institute of Chemical Processes, and BioMAX, Seoul National University, Seoul, 08826, Republic of Korea.
ORCID-Profile: Sangjun Moon, Byung-Soo Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Moon, S., Jung, M., Go, S., Hong, J., Sohn, H. S., Kim, C., Kang, M., Lee, B. J., Kim, J., Lim, J., & Kim, B. S. (2024). Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment. Advanced Materials, 36(44). https://doi.org/10.1002/adma.202410340
Vancouver
Moon S, Jung M, Go S, Hong J, Sohn HS, Kim C, et al. Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment. Advanced Materials. 2024;36(44). doi:10.1002/adma.202410340
BibTeX
@article{Moon2024,
author = {Moon, Sangjun and Jung, Mungyo and Go, Seokhyeong and Hong, Jihye and Sohn, Hee Su and Kim, Cheesue and Kang, Mikyung and Lee, Byung Joon and Kim, Jungwoo and Lim, Jinwoong and Kim, Byung-Soo},
title = {Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {44},
doi = {10.1002/adma.202410340}
}
EUVIMED